Atlantic Union Bankshares Corp Has $4.73 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Atlantic Union Bankshares Corp raised its position in Pfizer Inc. (NYSE:PFE) by 22.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,813 shares of the biopharmaceutical company’s stock after purchasing an additional 23,607 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Pfizer were worth $4,725,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. BlackRock Inc. raised its position in Pfizer by 0.6% during the first quarter. BlackRock Inc. now owns 445,384,893 shares of the biopharmaceutical company’s stock valued at $18,171,704,000 after acquiring an additional 2,516,132 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Pfizer by 9.8% in the 1st quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock valued at $8,932,423,000 after purchasing an additional 19,602,359 shares during the last quarter. Moneta Group Investment Advisors LLC increased its position in Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Geode Capital Management LLC raised its holdings in Pfizer by 0.5% during the first quarter. Geode Capital Management LLC now owns 109,852,779 shares of the biopharmaceutical company’s stock valued at $4,472,433,000 after buying an additional 577,201 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 14.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,901,181 shares of the biopharmaceutical company’s stock valued at $3,408,836,000 after acquiring an additional 10,560,702 shares during the last quarter. 68.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 target price on shares of Pfizer in a research report on Monday. Morgan Stanley dropped their target price on shares of Pfizer from $42.00 to $40.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 2nd. Truist Financial restated a “buy” rating and set a $62.00 price target on shares of Pfizer in a report on Wednesday, September 13th. Jefferies Financial Group cut their price objective on Pfizer from $40.00 to $38.00 in a research report on Wednesday, August 2nd. Finally, BMO Capital Markets reduced their price objective on Pfizer from $45.00 to $44.00 and set an “outperform” rating for the company in a research report on Wednesday, August 2nd. Twelve research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $46.35.

Pfizer Stock Performance

NYSE PFE opened at $33.64 on Tuesday. The firm has a market cap of $189.93 billion, a price-to-earnings ratio of 8.95, a PEG ratio of 1.14 and a beta of 0.59. The company has a current ratio of 2.12, a quick ratio of 1.82 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 1-year low of $33.44 and a 1-year high of $54.93. The company has a 50 day moving average of $35.80 and a 200-day moving average of $37.96.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.10. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $13.36 billion. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The business’s revenue for the quarter was down 54.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.04 EPS. On average, equities analysts forecast that Pfizer Inc. will post 3.33 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th were paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 4.88%. The ex-dividend date was Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is presently 43.62%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.